Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia
Souza, Alessandra R. [UNIFESP]
Braga, Josefina A. P. [UNIFESP]
Paiva, Terezinha M. de
Loggetto, Sandra R.
Azevedo, Raymundo S.
Weckx, Lily Y. [UNIFESP]
Is part ofVaccine
MetadataShow full item record
The immunogenicity and tolerability of virosome and of split influenza vaccines in patients with sickle cell anemia (SS) were evaluated Ninety SS patients from 8 to 34 years old were randomly assigned to receive either virosome (n = 43) or split vaccine (n = 47) Two blood samples were collected, one before and one 4-6 weeks after vaccination Antibodies against viral strains (2006) A/New Caledonia (H1N1), A/California (H3N2), B/Malaysia were determined using the hemagglutinin inhibition test Post-vaccine reactions were recorded over 7 days Seroconversion rates for HI NI, H3N2 and B were 65 1%. 60 4% and 83 7% for virosome vaccine, and 68 0%, 61 7% and 68 0% for split vaccine Seroprotection rates for HI NI, H3N2 e B were 100%. 97 6% and 69.7% for virosome. and 97 8%, 97 8% and 76 6% for split vaccine No severe adverse reactions were recorded Virosome and split vaccines in patients with sickle cell anemia were equally Immunogenic. with high seroconversion and seroprotection rates Both vaccines were well tolerated (C) 2009 Elsevier Ltd All rights reserved
CitationVaccine. Oxford: Elsevier B.V., v. 28, n. 4, p. 1117-1120, 2010.
SponsorshipBerna Biotech, Ltd. Laboratory, Switzerland
Centers for Disease Control and Prevention, Atlanta, USA
- EPM - Artigos